| Primary |
| Hyperparathyroidism Secondary |
81.3% |
| Dialysis |
13.5% |
| Drug Use For Unknown Indication |
1.0% |
| Hyperparathyroidism Primary |
1.0% |
| Hyperphosphataemia |
1.0% |
| Pre-existing Disease |
1.0% |
| Renal Failure Chronic |
1.0% |
|
| Skin Lesion |
10.7% |
| Ventricular Extrasystoles |
8.9% |
| Hypocalcaemia |
7.1% |
| Vomiting |
7.1% |
| Hypotension |
5.4% |
| Renal Failure |
5.4% |
| Sepsis |
5.4% |
| Thrombocytopenia |
5.4% |
| Treatment Noncompliance |
5.4% |
| Anaemia |
3.6% |
| Fluid Overload |
3.6% |
| Hospitalisation |
3.6% |
| Hyperparathyroidism Secondary |
3.6% |
| Hypersensitivity |
3.6% |
| Joint Swelling |
3.6% |
| Myocardial Infarction |
3.6% |
| Orthostatic Hypotension |
3.6% |
| Pancreatitis |
3.6% |
| Renal Failure Acute |
3.6% |
| Renal Transplant |
3.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
30.3% |
| Hyperparathyroidism Secondary |
14.4% |
| Hypertension |
12.1% |
| Hyperphosphataemia |
9.8% |
| Renal Failure Chronic |
5.3% |
| Hyperparathyroidism |
4.5% |
| Thrombosis Prophylaxis |
3.0% |
| Hyperlipidaemia |
2.3% |
| Myocardial Ischaemia |
2.3% |
| Alcoholic Liver Disease |
1.5% |
| Anaemia |
1.5% |
| Gastric Ulcer |
1.5% |
| Hyperparathyroidism Primary |
1.5% |
| Hyperuricaemia |
1.5% |
| Osteoporosis |
1.5% |
| Product Used For Unknown Indication |
1.5% |
| Rash |
1.5% |
| Secondary Hyperthyroidism |
1.5% |
| Secondary Hypothyroidism |
1.5% |
| Arthralgia |
0.8% |
|
| Treatment Noncompliance |
22.2% |
| Vomiting |
14.8% |
| Sinusitis |
11.1% |
| Liver Disorder |
7.4% |
| Thrombocytopenia |
7.4% |
| Bone Giant Cell Tumour |
3.7% |
| Calciphylaxis |
3.7% |
| Coma |
3.7% |
| Osteonecrosis |
3.7% |
| Renal Failure Acute |
3.7% |
| Somnolence |
3.7% |
| Sudden Death |
3.7% |
| Thyroid Cancer |
3.7% |
| Type 2 Diabetes Mellitus |
3.7% |
| Ventricular Arrhythmia |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.2% |
| Drug Use For Unknown Indication |
24.4% |
| Hyperparathyroidism Secondary |
7.9% |
| Hypertension |
7.4% |
| Renal Failure Chronic |
3.5% |
| Hyperparathyroidism |
3.4% |
| Peritoneal Dialysis |
3.3% |
| Renal Transplant |
3.3% |
| Anaemia |
3.2% |
| Hyperphosphataemia |
2.8% |
| Nuclear Magnetic Resonance Imaging |
2.2% |
| Pain |
1.4% |
| Osteoporosis |
1.2% |
| Nausea |
1.2% |
| Prophylaxis |
1.1% |
| Nephrogenic Anaemia |
1.0% |
| Anticoagulant Therapy |
0.9% |
| Constipation |
0.9% |
| Haemolytic Uraemic Syndrome |
0.9% |
| Angiogram |
0.8% |
|
| Vomiting |
11.0% |
| Death |
9.2% |
| Skin Induration |
8.3% |
| Urinary Tract Infection |
6.4% |
| Cardiac Failure |
5.5% |
| Encephalopathy |
5.5% |
| Gastrointestinal Disorder |
5.5% |
| Lower Respiratory Tract Infection |
5.5% |
| Pneumonia |
4.6% |
| Pyrexia |
4.6% |
| Gastric Ulcer |
3.7% |
| Gastroenteritis |
3.7% |
| Peritonitis Sclerosing |
3.7% |
| Premature Labour |
3.7% |
| Respiratory Tract Infection Viral |
3.7% |
| Staphylococcal Bacteraemia |
3.7% |
| Venous Insufficiency |
3.7% |
| Chest Pain |
2.8% |
| Delirium |
2.8% |
| Hypophosphataemia |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
24.7% |
| Product Used For Unknown Indication |
24.7% |
| Asymptomatic Hiv Infection |
19.8% |
| Hyperparathyroidism |
11.1% |
| Parathyroid Disorder |
9.9% |
| Hypertension |
2.5% |
| Dyslipidaemia |
1.2% |
| Osteoporosis |
1.2% |
| Pain |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
| Restless Legs Syndrome |
1.2% |
| Type 2 Diabetes Mellitus |
1.2% |
|
| Localised Oedema |
66.7% |
| Dyspnoea |
22.2% |
| Transaminases Increased |
11.1% |
|
